CRISPR Therapeutics AG
CRSP
Market Cap$3.3B
Close$
$-3.63
110.1% downside
Current Fair Value
110.1% downsideOvervalued by 110.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $3.30 Billion |
|---|---|
| Enterprise Value | $3.23 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $-4.34 |
| Beta | 1.84 |
| Outstanding Shares | 85,464,252 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | -8.93 |
|---|---|
| PEG | 38.19 |
| Price to Sales | 18.07 |
| Price to Book Ratio | 1.64 |
| Enterprise Value to Revenue | 16.04 |
| Enterprise Value to EBIT | -9.59 |
| Enterprise Value to Net Income | -14 |
| Total Debt to Enterprise | 0.07 |
| Debt to Equity | 0.12 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About CRISPR Therapeutics AG
CEO: Samarth Kulkarni